Acute Generalized Exanthematous Pustulosis After the First Dose of Favipiravir in a Patient with COVID-19 Pneumonia: A Case Report and Literature Review
Keywords:
acute generalized exanthematous pustulosis, AGEP, COVID-19Abstract
A 47-year-old man was referred to a hospital for treatment of coronavirus disease 2019 (COVID-19) pneumonia and developed progressive generalized pustular skin lesions over entire trunk, back and both upper extremities after the first dose of oral favipiravir for the treatment of his condition. No infectious causes of pustular lesions were identified upon investigations, and the diagnosis of acute generalized exanthematous pustulosis (AGEP) was made. With the prompt withdrawal of favipiravir, along with the initiation of systemic and topical corticosteroid treatment, his skin lesions resolved with desquamation and erythema within 3 days. Dermatologic adverse reactions from favipiravir, the novel antiviral agent for the treatment of SARS-COV2 infection, are uncommon. The association of favipiravir and acute generalized exanthematous pustulosis (AGEP), a severe form of skin reaction, remains unclear. We reported a case of patient who developed AGEP with the oral favipiravir as the causative agent.
References
Agrawal, U., Raju, R., & Udwadia, Z. F. (2020). Favipiravir: A new and emerging antiviral option in COVID-19. Medical Journal Armed Forces India, 76(4), 370-376. [cited 2021 August 23]; Available from: https://doi.org/10.1016/j.mjafi.2020.08.004
Alzahrani, M. J., Moussa, M. M., & Alfaraj, D. (2020). Acute Generalized Exanthematous Pustulosis After COVID-19 Infection: A Case Report From Saudi Arabia. Cureus, 12(11), e11609. [cited 2021 August 23]; Available from: https://doi.org/10.7759/cureus.11609
Atak, M. F., Farabi, B., Akbayrak, A., Kalelioglu, M. B., & Rao, B. K. (2021). Acute generalized exanthematous pustulosis following treatment with favipiravir in a patient with COVID-19 without hydroxychloroquine use: Report of the first case. Journal of Cosmetic Dermatology, 20(8), 2387-2389. [cited 2021 August 28]; Available from: https://doi.org/10.1111/jocd.14304
De, A., Das, S., Sarda, A., Pal, D., & Biswas, P. (2018). Acute Generalised Exanthematous Pustulosis: An Update. Indian journal of dermatology, 63(1), 22-29. [cited 2021 August 23]; Available from: https://doi.org/10.4103/ijd.IJD_581_17
Department of Medical Services. (2021). Clinical Practice Guideline on Diagnosis, Treatment and Infection Prevention and Control of COVID-19 for Medical Doctor and Public Helth Personnel. April 17, 2021.[Online]. [Cited 2021 August 28]; Available from: https://covid19.dms.go.th/Content/Select_Landding_page?contentId=119
Delaleu, J., Deniau, B., Battistella, M., de Masson, A., Bensaid, B., Jachiet, M., et al. (2020). Acute generalized exanthematous pustulosis induced by hydroxychloroquine prescribed for COVID-19. The Journal of Allergy and Clinical Immunology: in Practice, 8(8), 2777-2779. [cited 2021 August 23]; Available from: https://doi.org/10.1016/j.jaip.2020.05.046
Enos, T., Jeong, H. S., Vandergriff, T., Jacobe, H. T., & Chong, B. F. (2020). Acute generalized exanthematous pustulosis induced by empiric hydroxychloroquine for presumed COVID-19. Dermatologic therapy, 33(6), e13834. [cited 2021 August 23]; Available from: https://doi.org/10.1111/dth.13834
Hadavand, M. A., Kaffenberger, B., Cartron, A. M., & Trinidad, J. C. L. (2020). Clinical presentation and management of atypical and recalcitrant acute generalized exanthematous pustulosis. Journal of the American Academy of Dermatology. 87(3), 632–639. [cited 2021 August 23]; Available from: https://doi.org/10.1016/j.jaad.2020.09.024
Haraszti, S., Sendil, S., & Jensen, N. (2020). Delayed Presentation of Acute Generalized Exanthematous Pustulosis Following Treatment with Cefepime in a Patient with COVID-19 without the Use of Hydroxychloroquine. The American journal of case reports, 21, 1-4. [cited 2021 August 23]; Available from: https://doi.org/10.12659/AJCR.926901
Kaur, R. J., Charan, J., Dutta, S., Sharma, P., Bhardwaj, P., Sharma, P., et al. (2020). Favipiravir Use in COVID-19: Analysis of Suspected Adverse Drug Events Reported in the WHO Database. Infection and drug resistance, 13, 4427-4438. [cited 2021 August 23]; Available from: https://doi.org/10.2147/IDR.S287934
Litaiem, N., Hajlaoui, K., Karray, M., Slouma, M., & Zeglaoui, F. (2020). Acute generalized exanthematous pustulosis after COVID-19 treatment with hydroxychloroquine. Dermatologic Therapy, 33(4), e13565. [cited 2021 August 23]; Available from: https://doi.org/10.1111/dth.13565
Najar Nobari, N., Seirafianpour, F., Mashayekhi, F., & Goodarzi, A. (2021). A systematic review on treatment-related mucocutaneous reactions in COVID-19 patients. Dermatologic Therapy, 34(1), e14662. [cited 2021 August 28]; Available from: https://doi.org/10.1111/dth.14662
Ordoñez, N. A., Sepulveda, V. G., Vargas, L. P., & Moreno, J. M. (2021). COVID-19 presenting as acute generalized exanthematous pustulosis associated with multiorgan dysfunction in a 44-year-old female patient. Revista do Instituto de Medicina Tropical de Sao Paulo, 63, e42. [cited 2021 August 27]; Available from: https://doi.org/10.1590/S1678-9946202163042
Pezzarossa, E., Ungari, M., Caresana, G., Sagradi, F., Cimardi, L., Pan, A., et al. (2021). Acute Generalized Exanthematous Pustulosis (AGEP) in 12 Patients Treated for SARS-CoV-2 Positive Pneumonia. The American Journal of dermatopathology, 43(5), 342-348. [cited 2021 August 26]; Available from: https://doi.org/10.1097/DAD.0000000000001819
Shrestha, D. B., Budhathoki, P., Khadka, S., Shah, P. B., Pokharel, N., & Rashmi, P. (2020). Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis. Virology Journal, 17(1), 1-15. [cited 2021 August 23]; Available from: https://doi:10.1186/s12985-020-01412-z
Sidoroff, A., Dunant, A., Viboud, C., Halevy, S., Bavinck, J. N., Naldi, L., et al. (2007). Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR). The British Journal of Dermatology, 157(5), 989-996. [cited 2021 August 23]; Available from: https://doi.org/10.1111/j.1365-2133.2007.08156.x
Stingeni, L., Francisci, D., Bianchi, L., Hansel, K., Tramontana, M., Di Candilo, F., et al. (2021). Severe adverse drug reaction in SARS-CoV-2 infection: AGEP induced by ceftriaxone and confirmed by patch test. Contact Dermatitis, 85(3), 366-368. [cited 2021 August 23]; Available from: https://doi.org/10.1111/cod.13857
Suchonwanit, P., Leerunyakul, K., & Kositkuljorn, C. (2020). Cutaneous manifestations in COVID-19: Lessons learned from current evidence. Journal of the American Academy of Dermatology, 83(1), e57-e60. [cited 2021 August 23]; Available from: https://doi.org/10.1016/j.jaad.2020.04.094
Szatkowski, J., & Schwartz, R. A. (2015). Acute generalized exanthematous pustulosis (AGEP): A review and update. Journal of the American Academy of Dermatology, 73(5), 843-848. [cited 2021 August 23]; Available from: shttps://doi.org/10.1016/j.jaad.2015.07.017
